Effect of deferiprone or deferoxamine on right ventricular function in thalassemia major patients with myocardial iron overload

<p>Abstract</p> <p>Background</p> <p>Thalassaemia major (TM) patients need regular blood transfusions that lead to accumulation of iron and death from heart failure. Deferiprone has been reported to be superior to deferoxamine for the removal of cardiac iron and improve...

Full description

Bibliographic Details
Published in:	Journal of Cardiovascular Magnetic Resonance
Main Authors:	Gotsis Efstathios D, Aessopos Athanassios, Piga Antonio, Ladis Vasili, Karagiorga Markissia, Berdoukas Vasili, Alam Mohammed H, Carpenter John, Alpendurada Francisco, Smith Gillian C, Tanner Mark A, Westwood Mark A, Galanello Renzo, Roughton Michael, Pennell Dudley J
Format:	Article
Language:	English
Published:	Elsevier 2011-07-01
Online Access:	http://www.jcmr-online.com/content/13/1/34

Similar Items

Effects of combined deferiprone with deferoxamine on right ventricular function in thalassaemia major
by: Alpendurada Francisco, et al.
Published: (2012-01-01)

Cardiac magnetic resonance imaging R2* assessments and analysis of historical parameters in patients with transfusion-dependent thalassemia
by: Athanassios Aessopos, et al.
Published: (2007-01-01)

Comparative Efficacy of Deferiprone, Deferoxamine and Combination of Deferiprone and Deferoxamine on Serum Ferritin Value in Beta-Thalassemia Patients
by: Nargesbeygom Mirbehbahani, et al.
Published: (2015-01-01)

Prevention of Cardiomyopathy in Transfusion-Dependent Homozygous Thalassaemia Today and the Role of Cardiac Magnetic Resonance Imaging
by: Athanassios Aessopos, et al.
Published: (2009-01-01)

Comparison of Deferiprone to Deferasirox and Deferoxamine to Cardiac and Hepatic T2* MRI in Thalassemia Patients: Evidence-based Case Report
by: Pustika Amalia Wahidiyat, et al.
Published: (2018-06-01)

Comparison of Deferiprone to Deferasirox and Deferoxamine to Cardiac and Hepatic T2* MRI in Thalassemia Patients: Evidence-based Case Report
by: Pustika Amalia Wahidiyat, et al.
Published: (2018-06-01)

Comparative efficacy and safety of deferoxamine, deferiprone and deferasirox on severe thalassemia: a meta-analysis of 16 randomized controlled trials.
by: Sujian Xia, et al.
Published: (2013-01-01)

Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with nontransfusion-dependent thalassemia syndromes
by: Taher AT, et al.
Published: (2016-12-01)

Toward optimizing the use of deferasirox: potential benefits of combined use with deferoxamine
by: Robert W. Grady, et al.
Published: (2013-01-01)

A pilot trial of deferiprone for neurodegeneration with brain iron accumulation
by: Giovanni Abbruzzese, et al.
Published: (2011-11-01)

CARDIAC FUNCTION AND IRON CHELATION IN THALASSEMIA MAJOR AND INTERMEDIA: A REVIEW OF THE UNDERLYING PATHOPHYSIOLOGY AND APPROACH TO CHELATION MANAGEMENT
by: Athanasios Aessopos, et al.
Published: (2009-07-01)

Combined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction
by: Pibiri Martina, et al.
Published: (2008-02-01)

Efficacy and safety of deferoxamine, deferasirox and deferiprone triple iron chelator combination therapy for transfusion-dependent β-thalassaemia with very high iron overload: a protocol for randomised controlled clinical trial
by: Anuja Premawardhena, et al.
Published: (2024-02-01)

Impact of myocardial iron loading on right ventricular function
by: Kirk Paul, et al.
Published: (2009-01-01)

Low prevalence of fibrosis in thalassemia major assessed by late gadolinium enhancement cardiovascular magnetic resonance
by: Tanner Mark A, et al.
Published: (2011-01-01)

THE HISTORY OF DEFERIPRONE (L1) AND THE COMPLETE TREATMENT OF IRON OVERLOAD IN THALASSAEMIA
by: George J Kontoghiorghes, et al.
Published: (2020-01-01)

Combined Deferoxamine - Deferasirox in Treatment of Thalassemia Major with Iron Overload
by: Abdul Kareem A. Mahmood, et al.
Published: (2014-04-01)

Chelation Therapy with Oral Solution of Deferiprone in Transfusional Iron-Overloaded Children with Hemoglobinopathies
by: Alexandros Makis, et al.
Published: (2013-01-01)

The effect of spirulina in reducing iron overload in the heart compared to amlodipine and deferiprone in iron overloaded rats
by: مني السيد محمد شمس الدين, et al.
Published: (2026-04-01)

The optimisation of cardiac iron overload assessment by systolic imaging
by: He Taigang, et al.
Published: (2010-01-01)

Abstract: Deferoxamine Increases Breast Cancer Radiosensitivity
by: Kavitha Ranganathan, MD, et al.
Published: (2018-09-01)

On improvement in ejection fraction with iron chelation in thalassemia major and the risk of future heart failure
by: Carpenter JP, et al.
Published: (2011-09-01)

Prospective comparison on cardiac iron by MR in thalassemia major patients treated with combination deferipron-desferrioxamine versus deferipron and desferrioxamine in monoterapy
by: Ricchi Paolo, et al.
Published: (2011-02-01)

DECENTRALISED AUTONOMOUS SOCIETY THROUGH LARGE LANGUAGE MODELS’ BASED AGENTS: A PATHWAY TO EMPOWER SMALL COMMUNITIES
by: BRAGA, Vasili
Published: (2023-10-01)

Was liest du aus dem Bild? - Transkulturelles Bilderlesen im DaF-Unterricht
by: Vasili Bachtsevanidis
Published: (2015-03-01)

FOLKLORE REPERTOIRE FROM KORCHINSKI`S (1937) AND GHERSHFELD`S (1940) COLLECTIONS IN CONTEMPORARY VISION
by: DRAGOI VASILI
Published: (2019-12-01)

Synthesis of Deferiprone as a Widely Used Iron-Chelating Drug for the Treatment of Iron-Overload Diseases
by: Sara Sadeghian, et al.
Published: (2024-03-01)

Biventricular dimensions and function in pediatric sickle-cell disease and thalassemia major patients without cardiac iron
by: Meloni Antonella, et al.
Published: (2013-01-01)

Deferiprone protects against photoreceptor degeneration by inhibiting parthanatos
by: Beatriz Villarejo-Zori, et al.
Published: (2025-05-01)

Deferiprone or deferasirox for cardiac siderosis in beta-thalassemia major
by: Khaled M. Musallam, et al.
Published: (2011-02-01)

Antiplatelet activity of deferiprone through cyclooxygenase-1 inhibition
by: Ngan Thi Tran, et al.
Published: (2020-05-01)

A T2* MRI prospective survey on heart iron in thalassemia major patients treated with sequential deferiprone-desferrioxamine versus deferipron and desferrioxamine in monotherapy
by: Capra Marcello, et al.
Published: (2011-02-01)

Ameliorating Iron Overload in Intestinal Tissue of Adult Male Rats: Quercetin vs Deferoxamine
by: Arwa A. El-Sheikh, et al.
Published: (2018-01-01)

Histopathological Changes of Heart, Liver, and Duodenum in Iron Overload: ‎Comparing the Role of Quercetin with Deferoxamine
by: Muntasser A Awad, et al.
Published: (2023-12-01)

Iron-overload-induced ferroptosis in mouse cerebral toxoplasmosis promotes brain injury and could be inhibited by Deferiprone.
by: Chong Wang, et al.
Published: (2023-08-01)

Combination iron chelation therapy with deferiprone and deferasirox in iron-overloaded patients with transfusiondependent β-thalassemia major
by: Hossein Karami, et al.
Published: (2017-01-01)

Экспедиция в Эвенкийский хошун Внутренней Монголии 2013 г.
by: Vasili V. Ushnitsky
Published: (2016-06-01)

Меркитские принцессы на троне Монгольской империи
by: Vasili V. Ushnitsky
Published: (2016-08-01)

Происхождение саха: история вопроса
by: Vasili V. Ushnitsky
Published: (2016-06-01)

Мифы и сведения о племени туматов: Хакасия, Тува, Прибайкалье, Ленский край
by: Vasili V. Ushnitsky
Published: (2016-08-01)